A novel excipient pathway for recombinant albumin
How Merck qualified rice-derived rHSA as a novel excipient in ERVEBO, the first known approval of its kind in a human injectable vaccine.
Read case studyPerformance. Defined.
Recombinant Proteins & Cytokines
InVitria replaces animal-origin materials with GMP recombinant alternatives to improve performance while removing lot-to-lot variability, regulatory risk, and supply chain fragility in biomanufacturing and final formulation.
The InVitria platform












In the field
The data speaks. So do our partners.
How Merck qualified rice-derived rHSA as a novel excipient in ERVEBO, the first known approval of its kind in a human injectable vaccine.
Read case study
DiscGenics walks through its human-component-free process built on Cellastim S, Optiferrin and Exbumin.
View presentation
InVitria and distribution partner Evonik on taking animal-free albumin from cell banking through to therapy.
Watch webinar
Our CEO, Scott Deeter, on recombinant albumin as the excipient strategy behind the ERVEBO precedent.
View presentation
FluGen presents its M2SR influenza vaccine platform and its cell-based production approach.
View presentation
Mark Stathos, PhD shows how 1% Optibumin 25 rHSA protects lentiviral vector titer through holds, clarification, TFF, sterile filtration and freeze-thaw.
View presentationProducts by type
Original research, analytical data, and economic modeling from InVitria’s scientific and applications teams.
Contact us
Lot-specific Certificates of Analysis, application-specific guidance, performance data, and regulatory support.